Pasar al contenido principal

PAPEL DEL RECEPTOR EPITELIAL INTESTINAL DE GLUCOCORTICOIDES NR3C1 EN LA INFLAMACION Y EL CANCER COLONICOS

SAF2017-88457-R

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2017
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE GRANADA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Insulin crystals grown in short-peptide supramolecular hydrogels show enhanced thermal stability and slower release profile

  • Contreras-Montoya, Rafael
  • Arredondo Amador, María
  • Escolano Casado, Guillermo
  • Mañas Torres, Maria C.
  • González, Mercedes
  • Conejero Muriel, Mayte
  • Bhatia, Vaibhav
  • Díaz Mochón, Juan José
  • Martínez Augustin, Olga
  • Sánchez de Medina, Fermín
  • Lopez-Lopez, Modesto T.
  • Conejero-Lara, Francisco
  • Gavira Gallardo, J. A.
  • Álvarez de Cienfuegos, Luis
[EN] Protein therapeutics have a major role in medicine in that they are used to treat diverse pathologies. Their three-dimensional structures not only offer higher specificity and lower toxicity than small organic compounds but also make them less stable, limiting their in vivo half-life. Protein analogues obtained by recombinant DNA technology or by chemical modification and/or the use of drug delivery vehicles has been adopted to improve or modulate the in vivo pharmacological activity of proteins. Nevertheless, strategies to improve the shelf-life of protein pharmaceuticals have been less explored, which has challenged the preservation of their activity. Herein, we present a methodology that simultaneously increases the stability of proteins and modulates the release profile, and implement it with human insulin as a proof of concept. Two novel thermally stable insulin composite crystal formulations intended for the therapeutic treatment of diabetes are reported. These composite crystals have been obtained by crystallizing insulin in agarose and fluorenylmethoxycarbonyl-dialanine (Fmoc-AA) hydrogels. This process affords composite crystals, in which hydrogel fibers are occluded. The insulin in both crystalline formulations remains unaltered at 50 °C for 7 days. Differential scanning calorimetry, high-performance liquid chromatography, mass spectrometry, and in vivo studies have shown that insulin does not degrade after the heat treatment. The nature of the hydrogel modifies the physicochemical properties of the crystals. Crystals grown in Fmoc-AA hydrogel are more stable and have a slower dissolution rate than crystals grown in agarose. This methodology paves the way for the development of more stable protein pharmaceuticals overcoming some of the existing limitations., The research leading to these results has received funding from the “la Caixa” Banking Foundation CaixaImpulse program, EIT-Health PocPlus program, and the Ministry of Economy and Competitiveness of Spain, acknowledged through the following projects: BIO2016-74875-P, BFU2014-57736-P, AGL2014-58883-R, SAF2017-88457-R, AGL2017-85270-R, and FIS2017-85954-R co-funded by Fondo Europeo de Desarrollo Regional, ERDF, European Union, and FEDER/Junta de Andalucía-Consejería de Transformación Económica, Industria, Conocimiento y Universidades (Spain) projects P18-FR-3533, P12-FQM-2721, P12-FQM-790, CTS235, and CTS164. M.A.-A. and M.C.M.-T. were supported by fellowships from the Ministry of Education. CIBERehd is funded by Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Evidence for shared genetic risk factors between lymphangioleiomyomatosis and pulmonary function

  • Farré, Xavier
  • Espín, Roderic
  • Baiges, Alexandra
  • Blommaert, Eline
  • Kim, Wonji
  • Giannikou, Krinio
  • Herranz, Carmen
  • Román, Antonio
  • Sáez, Berta
  • Casanova, Álvaro
  • Ancochea, Julio
  • Valenzuela, Claudia
  • Ussetti, Piedad
  • Laporta, Rosalía
  • Rodríguez-Portal, José A.
  • Moorsel, Coline H. M. van
  • Vis, Joanne J. van der
  • Quanjel, Marian J. R.
  • Tena Garitaonaindia, Mireia
  • Sánchez de Medina, Fermín
  • Mateo, Francesca
  • Molina-Molina, María
  • Won, Sungho
  • Kwiatkowski, David J.
  • Cid, Rafael de
  • Pujana, Miguel Ángel
[Introduction] Lymphangioleiomyomatosis (LAM) is a rare low-grade metastasising disease characterised by cystic lung destruction. The genetic basis of LAM remains incompletely determined, and the disease cell-of-origin is uncertain. We analysed the possibility of a shared genetic basis between LAM and cancer, and LAM and pulmonary function., [Methods] The results of genome-wide association studies of LAM, 17 cancer types and spirometry measures (forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), FEV1/FVC ratio and peak expiratory flow (PEF)) were analysed for genetic correlations, shared genetic variants and causality. Genomic and transcriptomic data were examined, and immunodetection assays were performed to evaluate pleiotropic genes., [Results] There were no significant overall genetic correlations between LAM and cancer, but LAM correlated negatively with FVC and PEF, and a trend in the same direction was observed for FEV1. 22 shared genetic variants were uncovered between LAM and pulmonary function, while seven shared variants were identified between LAM and cancer. The LAM-pulmonary function shared genetics identified four pleiotropic genes previously recognised in LAM single-cell transcriptomes: ADAM12, BNC2, NR2F2 and SP5. We had previously associated NR2F2 variants with LAM, and we identified its functional partner NR3C1 as another pleotropic factor. NR3C1 expression was confirmed in LAM lung lesions. Another candidate pleiotropic factor, CNTN2, was found more abundant in plasma of LAM patients than that of healthy women., [Conclusions] This study suggests the existence of a common genetic aetiology between LAM and pulmonary function., This research was supported by Asociación Española de LAM; The LAM Foundation Seed Grant 2019; Carlos III Institute of Health grants PI18/01029, PI21/01306 and ICI19/00047 (co-funded by European Regional Development Fund (ERDF), “A way to build Europe”); Ministry of Economy and Competitivity grant SAF2017-88457-R; the Generalitat de Catalunya SGR 2017-449 and 2017-529; PERIS PFI-Salut SLT017-20-000076; and the CERCA Program to IDIBELL and Institut Germans Trias i Pujol. X. Farré is supported by the VEIS project (001-P-001647, ERDF Operational Programme of Catalonia 2014–2020; co-funded by ERDF, “A way to build Europe”)., Peer reviewed